{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:37:52Z","timestamp":1779320272211,"version":"3.51.4"},"reference-count":22,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"unspecified","delay-in-days":24,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2021,1,17]]},"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Although the Society for Immunotherapy of Cancer (SITC) Immunotherapy Resistance Taskforce recently defined primary and secondary resistance to anti-programmed cell death protein 1 (anti-PD-1) therapy, there is lack of real-world data regarding differences in these resistance subtypes with respect to radiological dynamics and clinical manifestations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We performed single-blind re-evaluations of radiological images by independent radiologists on a retrospectively assembled cohort of patients with advanced melanoma (n=254, median follow-up 31 months) receiving anti-PD-1 monotherapy at Massachusetts General Hospital and Peking University Cancer Hospital. Radiological characteristics and timing at multiple crucial time points were analyzed and correlated with each other and with survival. Primary and secondary resistance was defined as per the SITC Immunotherapy Resistance Taskforce definitions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The most significant target lesion measurement change took place within the first 3 months after anti-PD-1 initiation. Patients with stable disease with versus without tumor shrinkage at the initial evaluation exhibited distinct disease trajectory, as the rate of further upgrade to a partial or complete remission (CR\/PR) was 44% and 0%, respectively. Eleven per cent of PR patients ultimately achieved a CR. In multivariate analyses, deeper response depth was independently associated with a more limited progression pattern, fewer involved organs, lower tumor burden, slower growth rate at disease progression (PD) (all p\u22640.001), and longer post-progression survival (PPS) (bivariate analysis, p=0.005). Compared with primary resistance, secondary resistance was associated with less widespread PD pattern, lower tumor burden and slower tumor growth (all p\u22640.001). Patients with secondary resistance were less likely to receive further systemic therapy (28% vs 57%, p&lt;0.001) yet had significantly better PPS (HR 0.503, 95% CI 0.288 to 0.879, p=0.02).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Radiological dynamics were variable, yet significantly correlated with survival outcomes. SITC-defined primary and secondary resistance are distinct clinical manifestations in patients with melanoma, suggesting the possibility of resistance-type-based therapeutic decision-making and clinical trial design, once further validated by future prospective studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2020-002092","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T11:51:47Z","timestamp":1614253907000},"page":"e002092","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":13,"title":["Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort"],"prefix":"10.1136","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5203-4080","authenticated-orcid":false,"given":"Xue","family":"Bai","sequence":"first","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"},{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gyulnara","family":"Kasumova","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lu","family":"Si","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3458-461X","authenticated-orcid":false,"given":"Bixia","family":"Tang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanliang","family":"Cui","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Yang","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"},{"name":"Department of Medical Oncology, Shanxi Bethune Hospital, Taiyuan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoting","family":"Wei","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Cohen","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Freedman","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riley","family":"Fadden","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista","family":"Rubin","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatyana","family":"Sharova","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennie","family":"Frederick","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Flaherty","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryan","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Guo","sequence":"additional","affiliation":[{"name":"Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7522-6173","authenticated-orcid":false,"given":"Genevieve","family":"Boland","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"2025100306481356000_9.2.e002092.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2025100306481356000_9.2.e002092.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2025100306481356000_9.2.e002092.3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2386"},{"key":"2025100306481356000_9.2.e002092.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.01464"},{"key":"2025100306481356000_9.2.e002092.5","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.9508","article-title":"FDA analysis of depth of response (Dpr) and survival across 10 randomized controlled trials in patients with previously untreated unresectable or metastatic melanoma (Umm) by therapy type","volume":"37","author":"Osgood","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100306481356000_9.2.e002092.6","doi-asserted-by":"crossref","first-page":"3448","DOI":"10.1002\/cncr.32984","article-title":"Outcomes after progression of disease with anti-PD-1\/PD-L1 therapy for patients with advanced melanoma","volume":"126","author":"Patrinely","year":"2020","journal-title":"Cancer"},{"key":"2025100306481356000_9.2.e002092.7","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0513-4"},{"key":"2025100306481356000_9.2.e002092.8","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1093\/annonc\/mdz110","article-title":"Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma","volume":"30","author":"Jansen","year":"2019","journal-title":"Ann Oncol"},{"key":"2025100306481356000_9.2.e002092.9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0793"},{"key":"2025100306481356000_9.2.e002092.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-019-0116-x"},{"key":"2025100306481356000_9.2.e002092.11","doi-asserted-by":"crossref","first-page":"e522","DOI":"10.1016\/S1470-2045(15)00003-0","article-title":"Disease kinetics for decision-making in advanced melanoma: a call for scenario-driven strategy trials","volume":"16","author":"Grob","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025100306481356000_9.2.e002092.12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741"},{"key":"2025100306481356000_9.2.e002092.13","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2025100306481356000_9.2.e002092.14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398"},{"key":"2025100306481356000_9.2.e002092.15","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-16-0287"},{"key":"2025100306481356000_9.2.e002092.16","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1200\/JCO.19.00709","article-title":"Lesion-level response dynamics to programmed cell death protein (PD-1) blockade","volume":"37","author":"Osorio","year":"2019","journal-title":"J Clin Oncol"},{"key":"2025100306481356000_9.2.e002092.17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1"},{"key":"2025100306481356000_9.2.e002092.18","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1002\/cncr.32522","article-title":"Site-Specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy","volume":"126","author":"Pires da Silva","year":"2020","journal-title":"Cancer"},{"key":"2025100306481356000_9.2.e002092.19","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.ejca.2017.01.009","article-title":"Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma","volume":"75","author":"Zimmer","year":"2017","journal-title":"Eur J Cancer"},{"key":"2025100306481356000_9.2.e002092.20","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/cncr.31889","article-title":"Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1-based therapy","volume":"125","author":"Saab","year":"2019","journal-title":"Cancer"},{"key":"2025100306481356000_9.2.e002092.21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10005","article-title":"Ipilimumab (IPI) alone or in combination with anti-PD-1 (IPI+PD1) in patients (PTS) with metastatic melanoma (Mm) resistant to PD1 monotherapy","volume":"38","author":"Pires Da Silva","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025100306481356000_9.2.e002092.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.7837"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2020-002092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:48:27Z","timestamp":1759499307000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2020-002092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,25]]},"published-print":{"date-parts":[[2021,2]]}},"alternative-id":["10.1136\/jitc-2020-002092"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2020-002092","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2]]}}}